Loading...
XSTO
FLUO
Market cap57mUSD
Apr 11, Last price  
40.90SEK
1D
11.44%
1Q
-12.42%
IPO
752.08%
Name

Fluoguide AS

Chart & Performance

D1W1MN
P/E
—
P/S
885.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
77.60%
Rev. gr., 5y
%
Revenues
423k
-93.50%
0009,613,0006,511,000423,000
Net income
-38m
L+40.36%
-57,818-9,653,000-17,460,000-23,770,000-27,342,000-38,377,000
CFO
-29m
L-8.35%
-1,091-10,553,000-8,847,000-15,062,000-37,647,000-31,809,000-29,152,000
Earnings
May 28, 2025

Profile

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
URL
https://fluoguide.com/
IPO date
May 07, 2019
Employees
5
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
423
-93.50%
6,511
-32.27%
Cost of revenue
24,100
Unusual Expense (Income)
NOPBT
423
(17,589)
NOPBT Margin
100.00%
Operating Taxes
5,500
(5,500)
Tax Rate
1,300.24%
NOPAT
(5,077)
(12,089)
Net income
(38,377)
40.36%
(27,342)
15.03%
Dividends
Dividend yield
Proceeds from repurchase of equity
39,301
17,809
17,870
BB yield
-2.44%
-4.03%
Debt
Debt current
229
10,205
205
Long-term debt
1,019
1,451
205
Deferred revenue
Other long-term liabilities
1
1,809
Net debt
(17,360)
(10,012)
(25,603)
Cash flow
Cash from operating activities
(29,152)
(31,809)
(37,647)
CAPEX
(850)
(64)
Cash from investing activities
(987)
(37)
(117)
Cash from financing activities
27,080
27,500
17,019
FCF
(3,065)
(760)
(17,711)
Balance
Cash
18,608
21,668
26,013
Long term investments
Excess cash
18,608
21,647
25,687
Stockholders' equity
23,067
12,720
31,968
Invested Capital
5,083
10,828
6,486
ROIC
ROCE
1.80%
EV
Common stock shares outstanding
11,931
11,814
Price
39.15
-36.03%
61.20
63.20%
37.50
-56.29%
Market cap
730,162
64.81%
443,044
-54.38%
EV
720,150
417,441
EBITDA
456
688
(17,338)
EV/EBITDA
1,046.73
Interest
175
Interest/NOPBT